Methods for inhibiting ocular processes
OwnerDavid R. Hinton, Shikun He +1inventors
InventorsDavid R. Hinton, Shikun He, Noelynn A. Oliver
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for inhibiting or preventing ocular processes associated with CTGF. Methods and agents for use in treating or preventing ocular disorders, methods for diagnosing ocular disorders and related kits, and methods for screening for agents for use in the present methods are also provided.
Claims43
A method for inhibiting or preventing an ocular process associated with connective tissue growth factor (CTGF) in a subject, the method comprising administering an agent that decreases expression or activity of CTGF or fragments thereof.
A method for inhibiting or preventing ocular extracellular matrix production or deposition, the method comprising administering to a subject an agent that decreases expression or activity of CTGF or fragments thereof.
A method for inhibiting or preventing ocular neovascularization, the method comprising administering to a subject an agent that decreases expression or activity of CTGF or fragments thereof.
A method for inhibiting or preventing ocular inflammation, the method comprising administering to a subject an agent that decreases expression or activity of CTGF or fragments thereof.
A method for inhibiting or preventing ocular cell proliferation, the method comprising administering to a subject an agent that decreases expression or activity of CTGF or fragments thereof.
A method for inhibiting or preventing ocular cell migration, the method comprising administering to a subject an agent that decreases expression or activity of CTGF or fragments thereof.
A method for inhibiting or preventing ocular scarring, the method comprising administering to a subject an agent that decreases expression or activity of CTGF or fragments thereof.
A method for treating or preventing an ocular disorder, the method comprising administering to a subject an agent that decreases expression or activity of CTGF or fragments thereof.
A method for treating or preventing ocular fibrosis, the method comprising administering to a subject an agent that decreases expression or activity of CTGF or fragments thereof.
A method for treating or preventing an ocular disorder associated with neovascularization, the method comprising administering to a subject an agent that decreases expression or activity of CTGF or fragments thereof.
A method for treating or preventing an ocular disorder associated with extracellular matrix production or deposition, the method comprising administering to a subject an agent that decreases expression or activity of CTGF or fragments thereof.
A method for treating or preventing an ocular disorder associated with inflammation, the method comprising administering to a subject an agent that decreases expression or activity of CTGF or fragments thereof.
A method for treating or preventing an ocular disorder associated with cell proliferation, the method comprising administering to a subject an agent that decreases expression or activity of CTGF or fragments thereof.
A method for treating or preventing an ocular disorder associated with cell migration, the method comprising administering to a subject an agent that decreases expression or activity of CTGF or fragments thereof.
A method for treating or preventing a disorder associated with formation or alteration of an ocular membrane, the method comprising administering to a subject an agent that decreases expression or activity of CTGF or fragments thereof.
A method for maintaining or improving vision in a subject, the method comprising administering to the subject an effective amount of an agent that decreases expression or activity of CTGF or fragments thereof.
A method for diagnosing an ocular disorder associated with CTGF, or identifying a predisposition to develop an ocular disorder, the method comprising:
- (a) obtaining a sample from a subject;
- (b) quantitating the level of CTGF or fragments thereof in the sample;
- and
- (c) comparing the level of CTGF or fragments thereof in the sample to a standard level, wherein an increased amount of CTGF or fragments thereof in the sample is indicative of the presence of an ocular disorder or a predisposition to develop an ocular disorder.
A diagnostic kit for use in diagnosing an ocular disorder associated with CTGF, or identifying a predisposition to develop an ocular disorder associated with CTGF, the kit comprising:
- (a) a means for detecting the level of CTGF in a sample;
- and
- (b) a means for measuring the level of CTGF in the sample.
A diagnostic kit for use in diagnosing ocular fibrosis, or identifying a predisposition to develop ocular fibrosis, the kit comprising:
- (a) a means for detecting the level of CTGF in a sample;
- and
- (b) a means for measuring the level of CTGF in the sample.
A method for identifying an agent for use in inhibiting or preventing an ocular process associated with CTGF, the method comprising:
- (a) contacting a candidate agent with CTGF or a fragment thereof;
- (b) detecting the level of CTGF or CTGF fragment expression or activity in the sample;
- and
- (c) comparing the level of CTGF or CTGF fragment expression or activity in the sample to a standard level of CTGF or CTGF fragment expression or activity, wherein decreased expression and activity of CTGF or CTGF fragments in the sample is indicative of an agent that inhibits or prevents an ocular process associated with CTGF.
A method for identifying an agent for use in treating or preventing an ocular disorder associated with CTGF, the method comprising:
- (a) contacting a candidate agent with CTGF or CTGF fragments;
- (b) detecting the level of CTGF or CTGF fragment expression or activity in the sample;
- and
- (c) comparing the level of CTGF or CTGF fragment expression or activity in the sample to a standard level of CTGF or CTGF fragment expression or activity, wherein decreased expression and activity of CTGF or CTGF fragments in the sample is indicative of an agent that treats or prevents an ocular disorder associated with CTGF.
Dependencies are inferred from the claim text.